Navigation Links
Gentris Corporation Launches Next Generation Human Transcriptome Array
Date:9/16/2013

MORRISVILLE, N.C., Sept. 16, 2013 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip(R) Human Transcriptome Array (HTA) services. The GeneChip(R) HTA is a high resolution microarray for gene expression that is designed to empower next-generation expression profiling studies. The new array goes beyond gene-level expression profiling by providing the coverage and accuracy required to detect all known transcript isoforms produced by a gene.

(Logo:  http://photos.prnewswire.com/prnh/20130916/CL80771LOGO)

The human genome contains tens of thousands of genes, which are capable of producing hundreds of thousands of mRNA transcript isoforms. Changes in the production of these transcript isoforms have been implicated in a number of diseases including cancer. The Affymetrix GeneChip(R) HTA solves a critical need for efficient, high resolution mRNA transcript isoform analysis that does not require intensive bioinformatics and data analytics. The array covers 99% of human genes and 95% of all transcript isoforms produced from those genes. This unparalleled coverage provides deep insight into both coding and non-coding transcripts and provides a unique platform for profiling global gene expression in clinical trial patients.

"We are excited to be one of the first GCLP-compliant and CLIA-certified service providers to offer the Affymetrix GeneChip(R) HTA to our clients," said Amelia Wall-Warner, President, Gentris Corporation. "This new array provides a unique opportunity to advance translational medicine by cost-effectively providing insight into global gene expression of transcript isoforms in large clinical studies. The application of powerful next generation technologies like the GeneChip(R) HTA can drive major changes in personalized medicine and patient care."

The GeneChip(R) HTA generates a vast amount genetic data. In order to make the tremendous amount of data generated useful, Affymetrix provides the Affymetrix® Transcriptome Analysis Console (TAC) Software, which aids in the visualization of data and provides the capability to easily visualize expression changes at the gene and exon level as well as to drill down into alternatively spliced exons. The TAC software allows investigators to obtain biologically meaningful results in days rather than months.

The GeneChip(R) HTA combined with the simple, yet powerful TAC Software can help advance human disease research and clinical translational medicine by providing the most comprehensive view of the transcriptome offered in a commercial microarray and by supporting analysis solutions that enable researchers to obtain biologically-relevant results quickly without the need for complex bioinformatic analysis.

About Gentris Corporation
Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs. The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.

About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 23,700 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com.


'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Integrated Biorepository Receives Accreditation From The College of American Pathologists
2. Gentris Corporation Expands Headquarters, Biorepository
3. Gentris Corporation Announces Collaboration to Study Blood Stability
4. Gentris Corporation Launches New Pharmacogenomics Services
5. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
6. Euclid Systems Corporation signs agreement with Wenzhou Medical University to promote the use of Orthokeratology to control myopia progression
7. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Fourth Quarter
8. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
9. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
10. Unilife Corporation To Announce Financial Results For Fiscal Year 2013 Fourth Quarter And Year End On Tuesday, September 10, 2013
11. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... and Markets has announced the addition of the "Active Pharmaceutical ... The global active pharmaceutical ingredients (API) market is ... The rising prevalence of lifestyle-induced & age-related diseases and cancer is ... recombinant molecular technologies and high capitalization for development of novel drugs ...
(Date:2/28/2017)... SINGAPORE and SAN FRANCISCO , February 27, 2017 ... four Se D ... portfolio of biotechnology assets   LOI contemplates capital ... term growth plan for building shareholder value   Amarantus names ... interim-CFO of Amarantus   SeD Biomedical Inc. ...
(Date:2/28/2017)... February 28, 2017 The global  pulse oximeters market  is ... by Grand View Research, Inc. The pulse oximeters market is anticipated to witness ... prevalence of target diseases such as chronic obstructive pulmonary disease (COPD), sleep apnea, ... ... Grand View Research Logo ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... & Scientific Session on September 16-17 in Greenville, SC at the Bon Secours ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... Las Vegas ... revamped South Rancho location on Friday, March 10, 2017, 4-7 pm PST. For more ... but this clinic, located in the South Rancho neighborhood, has been renovated to provide ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... BrightStar Care ... of Choice Awards from Home Care Pulse. This award is granted only to top-ranking ... BrightStar Care Marietta is now ranked among home care providers from across the ...
(Date:2/27/2017)... ... 2017 , ... Bo Chen, PhD is the recipient of the 2017 ASLMS ... the Plenary Session at ASLMS 2017, the Annual Conference of the American Society for ... 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen will ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Robert E. Burke, ... medical group. But his impoverished upbringing and life experiences could have led him down ... Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a ...
Breaking Medicine News(10 mins):